Cargando…
Dose-Escalated Hypofractionated Intensity-Modulated Radiotherapy in High-Risk Carcinoma of the Prostate: Outcome and Late Toxicity
Background. The benefit of dose-escalated hypofractionated radiotherapy using intensity-modulated radiotherapy (IMRT) in prostate cancer is not established. We report 5-year outcome and long-term toxicity data within a phase II clinical trial. Materials and Methods. 60 men with predominantly high-ri...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388303/ https://www.ncbi.nlm.nih.gov/pubmed/22792470 http://dx.doi.org/10.1155/2012/450246 |
_version_ | 1782237166638727168 |
---|---|
author | Thomson, David Merrick, Sophie Swindell, Ric Coote, Joanna Kelly, Kay Stratford, Julie Wylie, James Cowan, Richard Elliott, Tony Logue, John Choudhury, Ananya Livsey, Jacqueline |
author_facet | Thomson, David Merrick, Sophie Swindell, Ric Coote, Joanna Kelly, Kay Stratford, Julie Wylie, James Cowan, Richard Elliott, Tony Logue, John Choudhury, Ananya Livsey, Jacqueline |
author_sort | Thomson, David |
collection | PubMed |
description | Background. The benefit of dose-escalated hypofractionated radiotherapy using intensity-modulated radiotherapy (IMRT) in prostate cancer is not established. We report 5-year outcome and long-term toxicity data within a phase II clinical trial. Materials and Methods. 60 men with predominantly high-risk prostate cancer were treated. All patients received neoadjuvant hormone therapy, completing up to 6 months in total. Thirty patients were treated with 57 Gy in 19 fractions and 30 patients with 60 Gy in 20 fractions. Acute and 2-year toxicities were reported and patients followed longitudinally to assess 5 year outcomes and long-term toxicity. Toxicity was measured using RTOG criteria and LENT/SOMA questionnaire. Results. Median followup was 84 months. Five-year overall survival (OS) was 83% and biochemical progression-free survival (bPFS) was 50% for 57 Gy. Five-year OS was 75% and bPFS 58% for 60 Gy. At 7 years, toxicity by RTOG criteria was acceptable with no grade 3 or above toxicity. Compared with baseline, there was no significant change in urinary symptoms at 2 or 7 years. Bowel symptoms were stable between 2 and 7 years. All patients continued to have significant sexual dysfunction. Conclusion. In high-risk prostate cancer, dose-escalated hypofractionated radiotherapy using IMRT results in encouraging outcomes and acceptable late toxicity. |
format | Online Article Text |
id | pubmed-3388303 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-33883032012-07-12 Dose-Escalated Hypofractionated Intensity-Modulated Radiotherapy in High-Risk Carcinoma of the Prostate: Outcome and Late Toxicity Thomson, David Merrick, Sophie Swindell, Ric Coote, Joanna Kelly, Kay Stratford, Julie Wylie, James Cowan, Richard Elliott, Tony Logue, John Choudhury, Ananya Livsey, Jacqueline Prostate Cancer Clinical Study Background. The benefit of dose-escalated hypofractionated radiotherapy using intensity-modulated radiotherapy (IMRT) in prostate cancer is not established. We report 5-year outcome and long-term toxicity data within a phase II clinical trial. Materials and Methods. 60 men with predominantly high-risk prostate cancer were treated. All patients received neoadjuvant hormone therapy, completing up to 6 months in total. Thirty patients were treated with 57 Gy in 19 fractions and 30 patients with 60 Gy in 20 fractions. Acute and 2-year toxicities were reported and patients followed longitudinally to assess 5 year outcomes and long-term toxicity. Toxicity was measured using RTOG criteria and LENT/SOMA questionnaire. Results. Median followup was 84 months. Five-year overall survival (OS) was 83% and biochemical progression-free survival (bPFS) was 50% for 57 Gy. Five-year OS was 75% and bPFS 58% for 60 Gy. At 7 years, toxicity by RTOG criteria was acceptable with no grade 3 or above toxicity. Compared with baseline, there was no significant change in urinary symptoms at 2 or 7 years. Bowel symptoms were stable between 2 and 7 years. All patients continued to have significant sexual dysfunction. Conclusion. In high-risk prostate cancer, dose-escalated hypofractionated radiotherapy using IMRT results in encouraging outcomes and acceptable late toxicity. Hindawi Publishing Corporation 2012 2012-06-20 /pmc/articles/PMC3388303/ /pubmed/22792470 http://dx.doi.org/10.1155/2012/450246 Text en Copyright © 2012 David Thomson et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Thomson, David Merrick, Sophie Swindell, Ric Coote, Joanna Kelly, Kay Stratford, Julie Wylie, James Cowan, Richard Elliott, Tony Logue, John Choudhury, Ananya Livsey, Jacqueline Dose-Escalated Hypofractionated Intensity-Modulated Radiotherapy in High-Risk Carcinoma of the Prostate: Outcome and Late Toxicity |
title | Dose-Escalated Hypofractionated Intensity-Modulated Radiotherapy in High-Risk Carcinoma of the Prostate: Outcome and Late Toxicity |
title_full | Dose-Escalated Hypofractionated Intensity-Modulated Radiotherapy in High-Risk Carcinoma of the Prostate: Outcome and Late Toxicity |
title_fullStr | Dose-Escalated Hypofractionated Intensity-Modulated Radiotherapy in High-Risk Carcinoma of the Prostate: Outcome and Late Toxicity |
title_full_unstemmed | Dose-Escalated Hypofractionated Intensity-Modulated Radiotherapy in High-Risk Carcinoma of the Prostate: Outcome and Late Toxicity |
title_short | Dose-Escalated Hypofractionated Intensity-Modulated Radiotherapy in High-Risk Carcinoma of the Prostate: Outcome and Late Toxicity |
title_sort | dose-escalated hypofractionated intensity-modulated radiotherapy in high-risk carcinoma of the prostate: outcome and late toxicity |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388303/ https://www.ncbi.nlm.nih.gov/pubmed/22792470 http://dx.doi.org/10.1155/2012/450246 |
work_keys_str_mv | AT thomsondavid doseescalatedhypofractionatedintensitymodulatedradiotherapyinhighriskcarcinomaoftheprostateoutcomeandlatetoxicity AT merricksophie doseescalatedhypofractionatedintensitymodulatedradiotherapyinhighriskcarcinomaoftheprostateoutcomeandlatetoxicity AT swindellric doseescalatedhypofractionatedintensitymodulatedradiotherapyinhighriskcarcinomaoftheprostateoutcomeandlatetoxicity AT cootejoanna doseescalatedhypofractionatedintensitymodulatedradiotherapyinhighriskcarcinomaoftheprostateoutcomeandlatetoxicity AT kellykay doseescalatedhypofractionatedintensitymodulatedradiotherapyinhighriskcarcinomaoftheprostateoutcomeandlatetoxicity AT stratfordjulie doseescalatedhypofractionatedintensitymodulatedradiotherapyinhighriskcarcinomaoftheprostateoutcomeandlatetoxicity AT wyliejames doseescalatedhypofractionatedintensitymodulatedradiotherapyinhighriskcarcinomaoftheprostateoutcomeandlatetoxicity AT cowanrichard doseescalatedhypofractionatedintensitymodulatedradiotherapyinhighriskcarcinomaoftheprostateoutcomeandlatetoxicity AT elliotttony doseescalatedhypofractionatedintensitymodulatedradiotherapyinhighriskcarcinomaoftheprostateoutcomeandlatetoxicity AT loguejohn doseescalatedhypofractionatedintensitymodulatedradiotherapyinhighriskcarcinomaoftheprostateoutcomeandlatetoxicity AT choudhuryananya doseescalatedhypofractionatedintensitymodulatedradiotherapyinhighriskcarcinomaoftheprostateoutcomeandlatetoxicity AT livseyjacqueline doseescalatedhypofractionatedintensitymodulatedradiotherapyinhighriskcarcinomaoftheprostateoutcomeandlatetoxicity |